The U.K.’s About-Face on Puberty Blockers for Children

T he United Kingdom is turning children into test experiments. When the government announced last year that it would ban the prescription of puberty blockers to minors, it seemed to mark a decisive turn: The country had absorbed the hard lessons spelled out in the Cass Review, an independent analysis of the consequences of transgender ideology for minors. The review was a turning point — not just for Britain, but for countries worldwide seeking to move away from the ideological capture wrought by transgender experimentation.

Unfortunately, following the Cass Review’s recommendation that any use of puberty blockers be confined to research, the National Health Service commissioned a major clinical trial. Known as PATHWAYS (Puberty Suppression and Transitional Healthcare with Adaptive Youth Services), the trial is now set to commence, involving around 220 children under the age of 16, including kids as young as ten. These young children will be subjected to dangerous puberty blockers in the name of “research.”

The idea that children can give informed consent to puberty blockers is indefensible. The Cass Review explicitly states that the rationale for early puberty suppression is “unclear” and that the long-term effects on brain development and psychological maturation are not understood. A child cannot meaningfully weigh risks that will manifest themselves decades later. These include very serious risks involving fertility, sexual function, and bone density, as well as the disastrous consequences of the surgical interventions that often follow puberty blockers. When experts cannot quantify the dangers, how can a ten-year-old possibly consent to them?

Cass found that the vast majority of children — 64 percent — placed on puberty blockers later went on to take cross-sex hormones. In other words, blockers do not function as a “pause button,” as activists have repeated for years. Rather, they are an on-ramp to often inevitable further interventions, including life-changing surgeries with permanent effects. Puberty blockers lock children into a trajectory of debilitating lifelong medical intervention, all in service of the lie that it is possible to be born in the wrong body.

Launching a clinical trial on minors with these kinds of consequences means children are in a very literal sense being experimented upon. This experimentation entails enrolling vulnerable children into protocols involving hormone suppression, data collection, psychological testing, and biological monitoring, even though multiple systematic reviews have confirmed that transgender interventions are rife with unknowns and hazards.

While Cass concluded that we don’t have sufficient evidence to say exactly how puberty blockers impact children in the long term, we certainly know enough to conclude that the consequences for children are cataclysmic. Insofar as puberty blockers are just the start of many children’s transgender journey, it is safe to state conclusively that the surgical removal of healthy body parts is never in the best interest of a child.

Furthermore, the idea that a trial with a primary endpoint at two years can capture long-term harms is absurd. Puberty develops over many years, as does fertility potential. Bone density, sexual maturation, cognitive development, and identity formation unfold over decades. A trial that ends after two years simply cannot tell us what will happen to these children at age 25, let alone 40. But the evidence we do have from — particularly from vocal detransitioners who have experienced the ill effects of this lie — reveals that the prognosis is grim.

Why is the U.K. willingly exposing its most vulnerable to these dangers? Following the Cass Review and the subsequent puberty blocker ban, Britain emerged as an international leader in the rejection of transgender ideology for minors. It was the first to draw the difficult conclusions others feared to confront in order to usher in a return to evidence-based medicine. But now, with this retreat, how many children will be harmed before policymakers come to their senses?

A proposed judicial review led by detransitioner Keira Bell and therapist James Esses has the potential to halt the trial before it begins. They contend that the National Health Service cannot lawfully authorize an experimental protocol on minors when the independent review it commissioned concluded that the evidence base for these interventions is weak. If the courts agree, the PATHWAYS trial could be struck down as contrary to the state’s duty to protect children from avoidable harm.

The Cass Review was commissioned precisely because too many children had already suffered — because the National Health Service had moved too fast, because ideology had overtaken evidence, and because the medical profession had subjected children to radically inappropriate and dangerous decisions they were too young to comprehend.

No child should ever be placed on puberty blockers, inside or outside a clinical trial. And not one more child should be made to be a test case for a perilous experiment predicated on the insidious deception that pills and surgeries can change your sex.